July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Umang Swami: Prior NHT in patients with MCRPC
May 8, 2024, 07:21

Umang Swami: Prior NHT in patients with MCRPC

Umang Swami, Assistant Professor in the Department of Oncology at Huntsman Cancer Institute, shared on X:

“Most patients (63%) diagnosed with Metastatic castration-resistant prostate cancer (mCRPC) (even in 2023) never received prior Neoadjuvant hormonal therapy (NHT). .

NHT remains the most common therapy in 1L mCRPC (even in patients treated with prior NHT).”

Umang Swami

Source: Umang Swami/X